Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $11.4M | $13.1M | $16.9M | $16.0M | $13.8M | $15.0M | $17.4M |
| Revenue growth | — | 14.7% | 29.2% | -5.1% | -13.9% | 8.9% | 16.0% |
| Gross profit | $8.66M | $10.4M | $12.6M | $10.0M | $8.27M | $9.02M | $10.5M |
| Gross margin | 76.0% | 79.7% | 74.6% | 62.5% | 59.9% | 60.0% | 60.4% |
| Operating income | -$10.6M | -$12.0M | -$20.4M | -$25.0M | -$17.3M | -$11.2M | -$19.9M |
| Operating margin | -92.8% | -92.1% | -120.7% | -156.2% | -125.3% | -74.3% | -114.1% |
| Net income | -$10.8M | -$12.1M | -$20.3M | -$23.8M | -$13.6M | -$11.1M | -$21.2M |
| Net margin | -94.4% | -92.3% | -120.2% | -148.8% | -98.4% | -74.1% | -121.4% |
| EPS (diluted) | -$0.95 | -$1.40 | -$0.96 | -$25.90 | -$11.14 | -$2.22 | -$2.07 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.34M | -$5.68M | -$15.7M | -$19.6M | -$11.9M | -$12.7M | -$15.3M |
| Capital expenditures | $176K | $120K | $2.40M | $924K | $803K | $568K | $2.34M |
| Free cash flow | -$5.52M | -$5.80M | -$18.1M | -$20.5M | -$12.7M | -$13.3M | -$17.6M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $469K | $18.2M | $24.0M | $3.52M | $1.64M | $6.26M | $2.03M |
| Total assets | $7.55M | $25.3M | $33.7M | $13.7M | $10.7M | $15.3M | $25.2M |
| Total liabilities | $9.18M | $8.41M | $8.15M | $8.92M | $10.3M | $7.33M | $26.7M |
| Long-term debt | $3.71M | $423K | $1.26M | — | — | — | $469K |
| Shareholders' equity | -$2.94M | $16.9M | $25.5M | $4.80M | $411K | $7.95M | -$1.49M |
| Retained earnings | -$23.3M | -$35.3M | -$55.6M | -$79.5M | -$93.1M | -$104M | -$125M |
| Shares (wtd avg diluted) | 12.4M | 18.2M | 21.2B | 921K | 1.22M | 5.02M | 10.3M |
Every figure is extracted from Vivos Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.